cannabis indica

Psicose

termo de indexação original: Psychosis

O acervo do Cannabis Indica reúne 407 estudos científicos que tocam a condição Psicose, publicados entre 1871 e 2024. Pela leitura automatizada, 145 (36%) foram classificados como favoráveis, 107 (26%) como inconclusivos e 155 (38%) como desfavoráveis — uma leitura de máquina, feita para navegar, não para concluir. O desenho mais frequente é metanálise (231 estudos), seguido de ensaio clínico duplo-cego (61). Os compostos mais presentes são Tetraidrocanabinol (THC), Endocanabinoide (não especificado) e Anandamida (AEA). Aparece com frequência ao lado de Esquizofrenia, Ansiedade e Efeitos Adversos da Cannabis.

Estudos indexados
407
Período coberto
1871–2024
Favoráveis
145 · 36%
Inconclusivos
107 · 26%
Desfavoráveis
155 · 38%
Termo original
Psychosis

O acervo em números

Tipo de estudo

Metanálise231
Ensaio Clínico Duplo-Cego61
Ensaio Clínico56
Metanálise Clínica34
Estudo em Animais20
Estudo Laboratorial5

Direção do resultado

Favorável145
Inconclusivo107
Desfavorável155

Por década

1870s1
1880s1
1890s1
1900s1
1970s1
1990s1
2000s20
2010s155
2020s226

407 estudos

Filtrar e buscar no acervo →

Esta página mostra 327 dos 407 estudos indexados sobre o tema, dos mais recentes aos mais antigos. Abra o acervo com este filtro para percorrer todos, ou baixe a lista completa em JSON e CSV.

  1. 2024

    Association between cannabis use disorder and schizophrenia stronger in young males than in females

    InconclusivoMetanáliseDependência QuímicaDependência — CannabisEsquizofrenia
  2. 2024

    Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes

    DesfavorávelMetanáliseAnsiedadeDepressãoDisfunção Cognitiva+4
  3. 2024

    Cannabidiol Therapy for Comorbid Schizophrenia and Addiction: A Guide for Clinical Practice

    FavorávelMetanálise ClínicaDependência QuímicaDependência — CannabisDependência — Opioides+6
  4. 2024

    Clinical Variables and Peripheral Biomarkers Associated with Substance-Induced Psychotic Disorder: Differences Related to Alcohol, Cannabis, and Psychostimulant Abuse

  5. 2024

    Endocannabinoid levels in female-sexed individuals with diagnosed depression: a systematic review

    InconclusivoMetanáliseAnsiedadeDepressãoEndocanabinoide (não especificado)
  6. 2024

    Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present)

  7. 2024

    Perioperative Cannabis Use in Bariatric Patients: A Review of Outcomes and Proposed Clinical Pathway for Management

    DesfavorávelMetanáliseDorDependência QuímicaEfeitos Adversos da Cannabis+9
  8. 2024

    Prenatal Cannabis Exposure and The Risk for Neuropsychiatric Anomalies in the Offspring: A Systematic Review and Meta-Analysis

    InconclusivoMetanáliseGestaçãoAlterações Cerebrais Neonatais
  9. 2024

    Problematic Consumption of Alcohol, Cannabis and Cigarettes—a German Nationwide Survey on Psychopathology, Stress, Mindfulness, and Quality of Life

  10. 2024

    Substance use and self-poisoning in schizophrenia: 11-year findings from a national clinical survey of suicide in mental health patients in England

  11. 2024

    The Interplay of Sleep Quality, Mental Health, and Sociodemographic and Clinical Factors among Italian College Freshmen

    DesfavorávelEnsaio ClínicoDependência QuímicaAnsiedadeDepressão+2
  12. 2024

    The Use of Compounds Derived from Cannabis sativa in the Treatment of Epilepsy, Painful Conditions, and Neuropsychiatric and Neurodegenerative Disorders

    FavorávelMetanáliseDorInflamaçãoEpilepsiaEndocanabinoide (não especificado)+2
  13. 2024

    Understanding youth and young adult cannabis use in Canada post-legalization: a scoping review on a public health issue

    FavorávelMetanáliseEfeitos Adversos da CannabisAnsiedadeDepressão+2
  14. 2023

    A case of clinical worsening after stereo-electroencephalographic-guided radiofrequency thermocoagulation in a patient with polymicrogyria

    FavorávelMetanáliseEpilepsia
  15. 2023

    A case of panic attack developing after THC-O acetate inhalation using an e-cigarette device

    DesfavorávelMetanáliseEfeitos Adversos da CannabisAnsiedadeDepressão+4
  16. 2023

    A systematic review of cannabidiol trials in neurodevelopmental disorders

    FavorávelMetanálise ClínicaDorInflamaçãoAnsiedadeAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+10
  17. 2023

    Associations of psychoactive substances and steroid hormones in hair: Findings relevant to stress research from a large cohort of young adults

  18. 2023

    Biobehavioral Interactions between Endocannabinoid and Hypothalamic-pituitary-adrenal Systems in Psychosis: A Systematic Review

  19. 2023

    Biomarkers in the cerebrospinal fluid of patients with psychotic disorders compared to healthy controls: a systematic review and meta-analysis

    FavorávelMetanálise ClínicaInflamaçãoAnandamida (AEA)
  20. 2023

    Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm - A Randomized Pilot Study

    FavorávelEnsaio Clínico Duplo-CegoDorCâncerDor — CrônicaTHC FarmacêuticoTHC:CBD Farmacêutico+8
  21. 2023

    Cannabidiol enhances cerebral glucose utilization and ameliorates psychopathology and cognition: A case report in a clinically high-risk mental state

  22. 2023

    Cannabis and Psychosis.

    DesfavorávelMetanálise
  23. 2023

    Cannabis use in Attention - Deficit/Hyperactivity Disorder (ADHD): A scoping review

    InconclusivoMetanáliseTDA e TDAH
  24. 2023

    Daily Cannabidiol Administration for 10 Weeks Modulates Hippocampal and Amygdalar Resting-State Functional Connectivity in Cannabis Users: A Functional Magnetic Resonance Imaging Open-Label Clinical Trial

  25. 2023

    Delta-8-THC association with psychosis: A case report with literature review

  26. 2023

    Does drug use affect the efficacy of amisulpride, aripiprazole and olanzapine in patients with schizophrenia spectrum disorders? Results from a pragmatic, randomised study

    InconclusivoEnsaio Clínico Duplo-CegoDependência QuímicaDependência — CannabisDependência — Opioides+4
  27. 2023

    Emerging adult perceptions of higher-risk cannabis consumption behaviours

  28. 2023

    Establishment of a point of departure for CBD hepatotoxicity employing human HepaRG spheroids

    InconclusivoEstudo LaboratorialCâncerInflamaçãoEpilepsiaTetraidrocanabinol (THC)CBD Farmacêutico+3
  29. 2023

    Factors associated with suicide in people who use drugs: a scoping review

    DesfavorávelMetanáliseDependência QuímicaDependência — CannabisAnsiedade+10
  30. 2023

    Gender differences in outcomes of early intervention services for first episode psychosis

    InconclusivoEnsaio ClínicoEsquizofreniaTranstornos de ComportamentoTranstorno Bipolar+1
  31. 2023

    How are young people’s mental health related to their sexual health and substance use? A systematic review of UK literature

    DesfavorávelMetanáliseDependência QuímicaDependência — CannabisAnsiedade+4
  32. 2023

    Incidence and Persistence of Psychotic Experiences in the General Population: Systematic Review and Meta-Analysis

    DesfavorávelMetanálise ClínicaDependência QuímicaEfeitos Adversos da Cannabis
  33. 2023

    Instant Detection of Synthetic Cannabinoids on Physical Matrices, Implemented on a Low-Cost, Ultraportable Device

  34. 2023

    Marijuana as a Cause of Diffuse Coronary Vasospasm Leading to Cardiac Arrest

  35. 2023

    Measuring white matter microstructure in 1,457 cannabis users and 1,441 controls: A systematic review of diffusion-weighted MRI studies

  36. 2023

    Molecular Insights into GPCR Mechanisms for Drugs of Abuse

  37. 2023

    Multinational Association of Supportive Care in Cancer (MASCC) guidelines: cannabis for psychological symptoms including insomnia, anxiety, and depression

    InconclusivoMetanálise ClínicaCâncerAnsiedadeDepressão+1
  38. 2023

    Prenatal THC exposure induces long-term, sex-dependent cognitive dysfunction associated with lipidomic and neuronal pathology in the prefrontal cortex-hippocampal network

  39. 2023

    Psychological Interventions for Cannabis Use among Adolescents and Young Adults: A Systematic Review

    FavorávelMetanálise ClínicaDependência QuímicaEfeitos Adversos da CannabisDependência — Cannabis+1
  40. 2023

    Quantitative Analysis of Three Synthetic Cannabinoids MDMB-4en-PINACA, ADB-BUTINACA, and ADB-4en-PINACA by Thermal-Assisted Carbon Fiber Ionization Mass Spectrometry

  41. 2023

    Questioning the role of palmitoylethanolamide in psychosis: a systematic review of clinical and preclinical evidence

  42. 2023

    Recreational Cannabis Use Over Time in Individuals at Clinical High Risk for Psychosis: Lack of Associations with Symptom, Neurocognitive, Functioning, and Treatment Patterns

    InconclusivoMetanáliseEsquizofrenia
  43. 2023

    Relationship between patterns of cannabis use and functional and symptomatic trajectories in first-episode psychosis

    DesfavorávelEnsaio ClínicoDepressãoEsquizofrenia
  44. 2023

    Retrospective chart review of substance abuse in patients with psychiatric emergencies in an emerging urban county

    DesfavorávelMetanáliseEfeitos Adversos da CannabisDependência — CannabisAnsiedade+8
  45. 2023

    Substance use and psychotic-like experiences in young people: a systematic review and meta-analysis

    DesfavorávelMetanáliseDependência QuímicaDependência — CannabisAnsiedade+6
  46. 2023

    Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder

  47. 2023

    The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experiment

    InconclusivoEnsaio Clínico Duplo-CegoEfeitos Adversos da CannabisDisfunção CognitivaTranstornos de Comportamento
  48. 2023

    The Effects of Peripubertal THC Exposure in Neurodevelopmental Rat Models of Psychopathology

  49. 2023

    The impact of legal cannabis availability on cannabis use and health outcomes: A systematic review

    DesfavorávelMetanáliseEfeitos Adversos da CannabisNáusea e VômitoGestação
  50. 2023

    The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial

  51. 2023

    The use of cannabidiol as a novel treatment for oral stereotypic behaviour (crib-biting) in a horse

    FavorávelEstudo em AnimaisDorInflamaçãoAnsiedadeEndocanabinoide (não especificado)+12
  52. 2023

    Turning down the spice: tackling the problems of synthetic cannabinoids

  53. 2023

    Use of psychoactive substances by goods carriage drivers associated with Kerala, India

  54. 2022

    A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy

  55. 2022

    A narrative review of molecular mechanism and therapeutic effect of Cannabidiol (CBD)

    FavorávelMetanáliseDorCâncerInflamação+5
  56. 2022

    A Review on the Bioactivity of Cannabinoids on Zebrafish Models: Emphasis on Neurodevelopment

    FavorávelMetanáliseDorCâncerAnsiedadeAnandamida (AEA)Tetraidrocanabinol (THC)+25
  57. 2022

    Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial

  58. 2022

    Adolescent cannabis use and later development of schizophrenia: An updated systematic review of longitudinal studies

    DesfavorávelMetanáliseEfeitos Adversos da CannabisEsquizofrenia
  59. 2022

    Altered White Matter Integrity at Illness Onset in Adolescents With a First Episode of Psychosis

    InconclusivoEnsaio Clínico
  60. 2022

    Anandamide Hydrolysis Inhibition Reverses the Long-Term Behavioral and Gene Expression Alterations Induced by MK-801 in Male Rats: Differential CB1 and CB2 Receptor-Mediated Effects

  61. 2022

    Association of cannabis potency with mental ill health and addiction: a systematic review

    DesfavorávelMetanálise ClínicaDependência QuímicaDependência — CannabisAnsiedadeTetraidrocanabinol (THC)+1
  62. 2022

    Ayahuasca-induced psychosis: A case report

    DesfavorávelMetanáliseEsquizofreniaAyahuasca
  63. 2022

    Ayahuasca-Induced Psychosis: A Case Report

    DesfavorávelMetanáliseInsônia e Distúrbios do SonoAyahuasca
  64. 2022

    Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder

    DesfavorávelMetanálise ClínicaDependência QuímicaEfeitos Adversos da CannabisDependência — Cannabis+3
  65. 2022

    Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses

    FavorávelEstudo em AnimaisDependência QuímicaAnsiedadeDepressãoÁcido Canabidiólico (CBD-a)+4
  66. 2022

    Cannabidiol in the context of substance use disorder treatment: A systematic review

  67. 2022

    Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer’s disease symptoms: a case report

    FavorávelMetanáliseInflamaçãoAnsiedadeDepressão+4
  68. 2022

    Cannabinoids in the management of behavioral, psychological, and motor symptoms of neurocognitive disorders: a mixed studies systematic review

  69. 2022

    Cannabinoids-Perspectives for Individual Treatment in Selected Patients: Analysis of the Case Series

  70. 2022

    Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis

    InconclusivoMetanálise ClínicaDorDor — CrônicaEsclerose MúltiplaTHC FarmacêuticoTHC:CBD Farmacêutico+1
  71. 2022

    Cannabis and the Violent Crime Surge

    DesfavorávelMetanáliseEfeitos Adversos da CannabisDepressãoEsquizofrenia+4
  72. 2022

    Cannabis induced psychosis: A systematic review on the role of genetic polymorphisms

    DesfavorávelMetanáliseEfeitos Adversos da Cannabis
  73. 2022

    Cannabis use and attenuated positive and negative symptoms in youth at clinical high risk for psychosis

    DesfavorávelMetanáliseDependência QuímicaDependência — Cannabis
  74. 2022

    Cannabis use and patterns of psychotic symptomatology in a longitudinal birth cohort

    InconclusivoMetanáliseEfeitos Adversos da CannabisEsquizofrenia
  75. 2022

    Cannabis Use in Autism: Reasons for Concern about Risk for Psychosis

  76. 2022

    Cannabis Vapor Exposure Alters Neural Circuit Oscillatory Activity in a Neurodevelopmental Model of Schizophrenia: Exploring the Differential Impact of Cannabis Constituents

    InconclusivoEstudo em AnimaisEsquizofrenia
  77. 2022

    Cannabis-Based Products for Chronic Pain : A Systematic Review

  78. 2022

    Capgras Syndrome Due to Cannabinoids Use: A Case Report With Radiological Findings

  79. 2022

    Clinical manifestations and serious adverse effects after cannabis use: role of age according to sex and coingestion of alcohol

  80. 2022

    Cognitive Behavioral Therapy Program for Cannabis Use Cessation in First-Episode Psychosis Patients: A 1-Year Randomized Controlled Trial

    FavorávelEnsaio ClínicoEfeitos Adversos da Cannabis
  81. 2022

    Cognitive functioning and cannabis use in first-episode psychosis

    InconclusivoMetanálise
  82. 2022

    Cutaneous Squamous Cell Carcinoma and Lichen Simplex Chronicus Successfully Treated with Topical Cannabinoid Oil: A Case Report and Summary of Cannabinoids in Dermatology

  83. 2022

    Delta-9-Tetrahydrocannabinol, Cannabidiol, and Acute Psychotomimetic States: A Balancing Act of the Principal Phyto-Cannabinoids on Human Brain and Behavior

    FavorávelEnsaio Clínico Duplo-CegoDisfunção CognitivaTranstornos de Comportamento
  84. 2022

    Does Cannabidiol Have a Benefit as a Supportive Care Drug in Cancer?

  85. 2022

    Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios

    InconclusivoEnsaio Clínico Duplo-CegoEfeitos Adversos da Cannabis
  86. 2022

    Does cannabis use predict aggressive or violent behavior in psychiatric populations? A systematic review

    InconclusivoMetanáliseAnsiedadeDepressãoDisfunção Cognitiva+4
  87. 2022

    Dopaminergic alterations in populations at increased risk for psychosis: A systematic review of imaging findings

    FavorávelMetanálise Clínica
  88. 2022

    Dropout Rates in Psychosocial Interventions for People With Both Severe Mental Illness and Substance Misuse: A Systematic Review and Meta-Analysis

    FavorávelMetanáliseDependência QuímicaEsquizofrenia
  89. 2022

    Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial

    FavorávelEnsaio Clínico Duplo-CegoEfeitos Adversos da CannabisAnsiedadeEpilepsiaTetraidrocanabinol (THC)+1
  90. 2022

    Effects of psychotropic drugs on ocular parameters relevant to traffic safety: A systematic review

    DesfavorávelMetanálise ClínicaEfeitos Adversos da Cannabis
  91. 2022

    Functional interactions between cannabinoids, omega-3 fatty acids, and peroxisome proliferator-activated receptors: Implications for mental health pharmacotherapies

    InconclusivoMetanáliseAnsiedadeDepressãoEsquizofrenia
  92. 2022

    Gender differences in the association between environment and psychosis

  93. 2022

    Global population attributable fraction of potentially modifiable risk factors for mental disorders: a meta-umbrella systematic review

    FavorávelMetanálise ClínicaDependência QuímicaDependência — CannabisAnsiedade+5
  94. 2022

    Harm Reduction Strategies among University Students Who Use Alcohol and Cannabis, and Related Psychological Variables: A Systematic Review

  95. 2022

    Identifying risk-thresholds for the association between frequency of cannabis use and development of cannabis use disorder: A systematic review and meta-analysis

  96. 2022

    Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders

  97. 2022

    Impact of cannabis use and its cessation on the dosage and the efficacy of antipsychotic drugs in in- and outpatients with schizophrenia taking medication: A systematic review and meta-analysis

    InconclusivoMetanálise ClínicaEfeitos Adversos da CannabisEsquizofrenia
  98. 2022

    Long-term effects of prenatal cannabis exposure: Pathways to adolescent and adult outcomes

  99. 2022

    Longitudinal effects of cannabis use on attentional processes in patients with first episode of psychosis

    DesfavorávelEnsaio ClínicoEfeitos Adversos da CannabisDependência — CannabisEsquizofrenia+1
  100. 2022

    Mechanisms of Cannabidiol (CBD) in Cancer Treatment: A Review

  101. 2022

    N-acetyl cysteine in the treatment of cannabis use disorder: A systematic review of clinical trials

  102. 2022

    Neuromodulation to Treat Substance Use Disorders in People With Schizophrenia and Other Psychoses: A Systematic Review

  103. 2022

    Neuroprotection of Cannabidiol, Its Synthetic Derivatives and Combination Preparations against Microglia-Mediated Neuroinflammation in Neurological Disorders

  104. 2022

    Neuropsychological functioning and suicidal behaviours in patients with first-episode psychosis: A systematic review

  105. 2022

    Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment

    DesfavorávelEnsaio Clínico Duplo-CegoDorDor — CrônicaDor — Neuropatia Periférica+3
  106. 2022

    Parkinson’s Disease and Dementia with Lewy Bodies, Patients Under Treatment with Standardized Extracts Enriched in Cannabidiol and Cannabigerol: Descriptive Observations in Preparation for a Phase 2a Clinical Trial

  107. 2022

    Penile self-amputation due to cannabis-induced psychosis: a case report

    DesfavorávelMetanáliseEfeitos Adversos da Cannabis
  108. 2022

    Potency and Therapeutic THC and CBD Ratios: U.S. Cannabis Markets Overshoot

  109. 2022

    Premorbid characteristics of patients with DSM-IV psychotic disorders

    DesfavorávelEnsaio ClínicoEsquizofreniaTranstorno Bipolar
  110. 2022

    Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition

    DesfavorávelMetanáliseDorDependência QuímicaCâncerTetraidrocanabinol (THC)+12
  111. 2022

    Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada

    FavorávelMetanáliseDorDor — CrônicaDepressão+5
  112. 2022

    Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis

    DesfavorávelMetanáliseEfeitos Adversos da CannabisAnsiedadeDepressão+2
  113. 2022

    Recreational cannabis legalizations associated with reductions in prescription drug utilization among Medicaid enrollees

    FavorávelMetanáliseDorAnsiedadeDor — Crônica+3
  114. 2022

    Risks and Benefits of Cannabis and Cannabinoids in Psychiatry

    InconclusivoMetanálise Clínica
  115. 2022

    Role of Cannabinoids in Various Diseases: A Review

  116. 2022

    Shifting the Paradigm on Cannabis Safety

    DesfavorávelMetanáliseCâncerInflamaçãoEfeitos Adversos da CannabisCBD Farmacêutico+16
  117. 2022

    Substance-induced psychosis and cognitive functioning: A systematic review

    DesfavorávelMetanáliseDependência QuímicaDisfunção CognitivaEsquizofrenia
  118. 2022

    Syndrome of Inappropriate Antidiuretic Hormone Secretion Following Ayahuasca Use in a Satanic Ritual: A Case Report

  119. 2022

    Terpene-Enriched CBD oil for treating autism-derived symptoms unresponsive to pure CBD: Case report

  120. 2022

    The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study

  121. 2022

    The Autism–Psychosis Continuum Conundrum: Exploring the Role of the Endocannabinoid System

    InconclusivoMetanáliseEsquizofreniaAutismoAnandamida (AEA)Tetraidrocanabinol (THC)+3
  122. 2022

    The Cannabis-Induced Epigenetic Regulation of Genes Associated with Major Depressive Disorder

  123. 2022

    The Effectiveness and Safety of Cannabidiol in Non-seizure-related Indications: A Systematic Review of Published Randomized Clinical Trials

  124. 2022

    The Effects of Cannabidiol and δ-9-Tetrahydrocannabinol in Social Cognition: A Naturalistic Controlled Study

  125. 2022

    The mental health of young people who are not in education, employment, or training: a systematic review and meta-analysis

    FavorávelMetanáliseDependência QuímicaDependência — CannabisAnsiedade+3
  126. 2022

    Unknown risks of psychosis and addiction with delta-8-THC: A call for research, regulation, and clinical caution

    InconclusivoMetanáliseEfeitos Adversos da CannabisDelta-8-THC
  127. 2022

    Variations of cannabis-related adverse mental health and addiction outcomes across adolescence and adulthood: A scoping review

  128. 2021

    [Efficacy of psychedelics in psychiatry, a systematic review of the literature]

    FavorávelMetanálise ClínicaDependência QuímicaDependência — CannabisAnsiedadeAyahuasca+7
  129. 2021

    A latent class analysis of cannabis use products in a general population sample of adolescents and their association with paranoia, hallucinations, cognitive disorganisation and grandiosity

    DesfavorávelEnsaio ClínicoEfeitos Adversos da CannabisAnsiedadeInsônia e Distúrbios do Sono
  130. 2021

    A primer on medicinal cannabis safety and potential adverse effects

  131. 2021

    A scoping review of the use of cannabidiol in psychiatric disorders

    FavorávelMetanálise ClínicaDependência — CannabisAnsiedadeDependência — Opioides+4
  132. 2021

    A systematic review and meta-analysis of sex differences in cannabis use disorder amongst people with comorbid mental illness

    DesfavorávelMetanálise ClínicaDependência QuímicaDependência — CannabisDepressão+2
  133. 2021

    A systematic review of longitudinal studies investigating the impact of cannabis use in patients with psychotic disorders

    DesfavorávelMetanáliseEfeitos Adversos da Cannabis
  134. 2021

    A systematic review of neuroimaging and acute cannabis exposure in age-of-risk for psychosis

    InconclusivoMetanáliseEsquizofrenia
  135. 2021

    Acute effects of cannabis on speech illusions and psychotic-like symptoms: two studies testing the moderating effects of cannabidiol and adolescence

    DesfavorávelMetanálise ClínicaEfeitos Adversos da Cannabis
  136. 2021

    Adolescent cannabis use and adult psychoticism: A longitudinal co-twin control analysis using data from two cohorts

    InconclusivoMetanálise
  137. 2021

    Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: a preliminary report

    FavorávelEnsaio Clínico Duplo-CegoAnsiedade
  138. 2021

    Annual incidence of cannabis-induced psychosis, other substance-induced psychoses and dually diagnosed schizophrenia and cannabis use disorder in Denmark from 1994 to 2016

    DesfavorávelMetanáliseEfeitos Adversos da CannabisEsquizofrenia
  139. 2021

    Antipsychotic Treatment Failure: A Systematic Review on Risk Factors and Interventions for Treatment Adherence in Psychosis

  140. 2021

    Are psychotic-like experiences related to a discontinuation of cannabis consumption in young adults?

    InconclusivoMetanálise
  141. 2021

    Cannabidiol (CBD) as a novel treatment in the early phases of psychosis

    FavorávelMetanáliseAnsiedadeDepressãoEsquizofrenia
  142. 2021

    Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial

    FavorávelEnsaio Clínico Duplo-CegoEsquizofreniaAnandamida (AEA)
  143. 2021

    Cannabidiol and mental health: possibilities, uncertainties, and controversies for addiction treatment

    InconclusivoMetanáliseDependência QuímicaAnsiedadeDepressão+10
  144. 2021

    Cannabidiol and Neurodevelopmental Disorders in Children

  145. 2021

    Cannabidiol Attenuates MK-801-Induced Cognitive Symptoms of Schizophrenia in the Passive Avoidance Test in Mice

    FavorávelEstudo em AnimaisDisfunção CognitivaEsquizofrenia
  146. 2021

    Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders - A Randomized, Open-Label Pilot-Study

    FavorávelEnsaio Clínico Duplo-Cego
  147. 2021

    Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13

    FavorávelEstudo LaboratorialInflamaçãoEstresse OxidativoEsquizofrenia
  148. 2021

    Cannabidiol modulation of hippocampal glutamate in early psychosis

    FavorávelEnsaio Clínico Duplo-CegoEsquizofreniaDependência — Estimulantes
  149. 2021

    Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum

    FavorávelEstudo em AnimaisEsquizofrenia
  150. 2021

    Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial

    InconclusivoEnsaio Clínico Duplo-CegoDependência QuímicaDependência — Cannabis
  151. 2021

    Cannabigerol and cannabichromene in Cannabis sativa L.

  152. 2021

    Cannabinoid control of hippocampal functions: the where matters

  153. 2021

    Cannabinoid receptor type 2 gene is associated with comorbidity of schizophrenia and cannabis dependence and fatty acid amide hydrolase gene is associated with cannabis dependence in the Spanish population

  154. 2021

    Cannabinoids, reward processing, and psychosis

    InconclusivoMetanálise
  155. 2021

    Cannabis exposure during adolescence: A uniquely sensitive period for neurobiological effects

  156. 2021

    Cannabis use and posttraumatic stress disorder comorbidity: Epidemiology, biology and the potential for novel treatment approaches

    InconclusivoMetanáliseDependência — CannabisAnsiedadeTEPT
  157. 2021

    Cannabis use in adolescence and risk of psychosis: Are there factors that moderate this relationship? A systematic review and meta-analysis

    DesfavorávelMetanáliseDependência QuímicaDependência — Cannabis
  158. 2021

    Cannabis use, self-perceived risk, perceived peer approval and parental attitudes among youth at clinical high-risk for psychosis

    DesfavorávelMetanálise
  159. 2021

    Cannabis-Induced Mania Following COVID-19 Self-Medication: A Wake-Up Call to Improve Community Awareness

    DesfavorávelMetanáliseEfeitos Adversos da CannabisCOVID-19Transtorno Bipolar
  160. 2021

    Cannabis, schizophrenia genetic risk, and psychotic experiences: a cross-sectional study of 109,308 participants from the UK Biobank

    DesfavorávelMetanáliseEsquizofrenia
  161. 2021

    Cognitive performance and lifetime cannabis use in patients with first-episode schizophrenia spectrum disorder

    FavorávelEnsaio ClínicoEfeitos Adversos da CannabisEsquizofrenia
  162. 2021

    Creatine kinase levels in psychotic patients who use cannabinoids

    InconclusivoMetanálise
  163. 2021

    Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: Analyses in patients and in perinatal Δ9-tetrahydrocannabinol-exposed rats

    FavorávelEstudo em AnimaisEsquizofreniaTetraidrocanabinol (THC)
  164. 2021

    Does cannabis use in adolescence predict self‐harm or suicide? Results from a Finnish Birth Cohort Study

  165. 2021

    Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review

    FavorávelMetanálise ClínicaDependência QuímicaDependência — CannabisEsquizofrenia
  166. 2021

    Endocannabinoid system mediates the association between gut-microbial diversity and anhedonia/amotivation in a general population cohort

  167. 2021

    Endocannabinoid-serotonin systems interaction in health and disease

  168. 2021

    Endocannabinoids and cortical plasticity: CB1R as a possible regulator of the excitation/inhibition balance in health and disease

    FavorávelMetanáliseEsquizofreniaEndocanabinoide (não especificado)
  169. 2021

    Endogenous antagonists of N-methyl-d-aspartate receptor in schizophrenia

    InconclusivoMetanáliseEsquizofreniaEndocanabinoide (não especificado)
  170. 2021

    Experimentally exploring the potential behavioral effects of personalized genetic information about marijuana and schizophrenia risk

    FavorávelEnsaio ClínicoDependência QuímicaDependência — CannabisEsquizofrenia+1
  171. 2021

    From heavy cannabis use to psychosis: is it time to take action?

    DesfavorávelMetanálise
  172. 2021

    From the Clinic to the Laboratory, and Back Again: Investigations on Cannabinoids and Endocannabinoid System Modulators for Treating Schizophrenia

  173. 2021

    Human Laboratory Models of Cannabis Use: Applications for Clinical and Translational Psychiatry Research

    FavorávelMetanáliseDorDependência QuímicaCâncer+16
  174. 2021

    Lethal case of myocardial ischemia following overdose of the synthetic cannabinoid ADB-FUBINACA

  175. 2021

    Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review

  176. 2021

    Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review

    InconclusivoMetanáliseDorAnsiedadeDor — Crônica+3
  177. 2021

    New Pharmacological Targets for the Treatment of Schizophrenia: A Literature Review

    FavorávelMetanáliseEsquizofreniaCBD Farmacêutico
  178. 2021

    New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature

  179. 2021

    Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis

    FavorávelMetanálise
  180. 2021

    Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study

    FavorávelEnsaio Clínico Duplo-CegoEsquizofrenia
  181. 2021

    Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment

    InconclusivoMetanáliseEsquizofreniaEndocanabinoide (não especificado)
  182. 2021

    Plasmatic endocannabinoids are decreased in subjects with ultra-high risk of psychosis

    FavorávelMetanáliseEsquizofreniaAnandamida (AEA)2-Araquidonoilglicerol (2-AG)
  183. 2021

    PPARγ receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice

    FavorávelEstudo em AnimaisInflamaçãoDisfunção CognitivaDoenças Neurodegenerativas
  184. 2021

    Predictors and moderators of marijuana and heavy alcohol use outcomes in adolescents treated for co-occurring substance use and psychiatric disorders in a randomized controlled trial

  185. 2021

    Preventive interventions targeting cannabis use and related harms in people with psychosis: A systematic review

    InconclusivoMetanáliseDependência QuímicaDependência — Cannabis
  186. 2021

    Psychosis induced by abuse of ayahuasca: a case report

    DesfavorávelMetanáliseAnsiedadeDepressãoEsquizofreniaAyahuasca+1
  187. 2021

    Psychosocial and pharmacological treatments for cannabis use disorder and mental health comorbidities: a narrative review

    InconclusivoMetanáliseDependência QuímicaDependência — CannabisAnsiedade+1
  188. 2021

    Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis

    DesfavorávelEnsaio Clínico Duplo-CegoCanabinoides Sintéticos JWH-x
  189. 2021

    Relationship between cannabis use and psychotic experiences in college students

    DesfavorávelMetanálise
  190. 2021

    Reversing the Psychiatric Effects of Neurodevelopmental Cannabinoid Exposure: Exploring Pharmacotherapeutic Interventions for Symptom Improvement

    DesfavorávelMetanáliseAnsiedadeDisfunção CognitivaEsquizofrenia+1
  191. 2021

    Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders

  192. 2021

    Schizophrenia and the Environment: Within-Person Analyses May be Required to Yield Evidence of Unconfounded and Causal Association-The Example of Cannabis and Psychosis

    DesfavorávelMetanáliseEfeitos Adversos da Cannabis
  193. 2021

    Sensory gating in tobacco-naïve cannabis users is unaffected by acute nicotine administration

    InconclusivoEnsaio Clínico Duplo-CegoEfeitos Adversos da CannabisDisfunção CognitivaEsquizofrenia+1
  194. 2021

    Sex-Specific Cannabidiol- and Iloperidone-Induced Neuronal Activity Changes in an In Vitro MAM Model System of Schizophrenia

    InconclusivoEstudo em AnimaisEsquizofrenia
  195. 2021

    The antipsychotic potential of cannabidiol: clinical implications for patients with psychosis and comorbid cannabis use disorder

  196. 2021

    The association of cannabis use with quality of life and psychosocial functioning in psychosis

    DesfavorávelMetanálise
  197. 2021

    The Effects of Acute Δ 9-Tetrahydrocannabinol on Striatal Glutamatergic Function: A Proton Magnetic Resonance Spectroscopy Study

    InconclusivoEnsaio Clínico Duplo-Cego
  198. 2021

    The endocannabinoid system as a therapeutic target for schizophrenia: Failures and potentials

    FavorávelMetanáliseEsquizofrenia
  199. 2021

    The Impact of THC and CBD in Schizophrenia: A Systematic Review

  200. 2021

    The independent and combined effects of cannabis use and systemic inflammation during the early stages of psychosis: exploring the two-hit hypothesis

    DesfavorávelMetanálise
  201. 2021

    The relationship between cannabis and schizophrenia: a genetically informed perspective

    DesfavorávelMetanáliseDependência — CannabisEsquizofrenia
  202. 2021

    The Yin and Yang of Cannabis: A Systematic Review of Human Neuroimaging Evidence of the Differential Effects of Δ 9-Tetrahydrocannabinol and Cannabidiol

    FavorávelMetanálise
  203. 2021

    Universal and Selective Interventions to Prevent Poor Mental Health Outcomes in Young People: Systematic Review and Meta-analysis

    FavorávelMetanáliseDependência QuímicaDependência — CannabisAnsiedade+7
  204. 2021

    When Cannabis Use Goes Wrong: Mental Health Side Effects of Cannabis Use That Present to Emergency Services

    DesfavorávelMetanáliseEfeitos Adversos da CannabisAnsiedadeEsquizofrenia+1
  205. 2020

    A contingency management intervention to reduce cannabis use and time to relapse in early psychosis: the CIRCLE RCT

    InconclusivoEnsaio Clínico Duplo-CegoDependência QuímicaEfeitos Adversos da CannabisDependência — Cannabis
  206. 2020

    A Little Dab Will Do: A Case of Cannabis-Induced Psychosis

    DesfavorávelMetanáliseEfeitos Adversos da CannabisDependência — CannabisAnsiedade+4
  207. 2020

    A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis

    FavorávelEnsaio Clínico Duplo-CegoAnsiedadeDisfunção CognitivaEsquizofreniaAnandamida (AEA)
  208. 2020

    Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment

    FavorávelEstudo em AnimaisEsquizofrenia
  209. 2020

    Ayahuasca - religion, life-style or drug?

    InconclusivoMetanáliseEsquizofreniaAyahuasca
  210. 2020

    Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders

    FavorávelMetanáliseAnsiedadeDepressão
  211. 2020

    Cannabinoid Hyperemesis Syndrome: A Case Report and Discussion Regarding Patients with Concurrent Disorders

    DesfavorávelMetanáliseDorEfeitos Adversos da CannabisDepressão+9
  212. 2020

    Cannabis-induced psychosis: clinical characteristics and its differentiation from schizophrenia with and without cannabis use

    DesfavorávelMetanálise
  213. 2020

    Cannabis, nicotine and the negative symptoms of schizophrenia: Systematic review and meta-analysis of observational studies

    FavorávelMetanáliseDependência QuímicaDependência — CannabisEsquizofrenia+1
  214. 2020

    Dosage, Efficacy and Safety of Cannabidiol Administration in Adults: A Systematic Review of Human Trials

    FavorávelMetanálise ClínicaAnsiedadeEsquizofrenia
  215. 2020

    Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers

    InconclusivoEnsaio Clínico Duplo-CegoDisfunção CognitivaEsquizofreniaTHC Farmacêutico
  216. 2020

    Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis

    DesfavorávelEnsaio Clínico Duplo-CegoAnsiedade
  217. 2020

    Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review

    FavorávelMetanáliseAnsiedadeDepressãoInsônia e Distúrbios do Sono+3
  218. 2020

    Moderating role of cannabis use between insight and depression in early psychosis

    InconclusivoMetanáliseDepressãoEsquizofrenia
  219. 2020

    Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis

    DesfavorávelMetanálise ClínicaAnsiedadeDepressãoDisfunção Cognitiva
  220. 2020

    Synthetic Cannabinoids and Its Association With Persistent Negative Symptoms of Schizophrenia

  221. 2020

    Terpenes/Terpenoids in Cannabis: Are They Important?

    FavorávelMetanáliseDorCâncerInflamação+10
  222. 2020

    The Changing Legal Landscape of Cannabis Use and Its Role in Youth-onset Psychosis

    InconclusivoMetanáliseEsquizofrenia
  223. 2020

    The effects of acute cannabidiol on cerebral blood flow and its relationship to memory: An arterial spin labelling magnetic resonance imaging study

  224. 2020

    The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders

    FavorávelMetanáliseAnsiedadeDepressãoEsquizofreniaMicrobioma+5
  225. 2020

    Therapeutic Efficacy of Cannabidiol (CBD): A Review of the Evidence from Clinical Trials and Human Laboratory Studies

    InconclusivoMetanáliseDorDependência QuímicaInflamação+6
  226. 2020

    Therapeutic potential of ayahuasca in grief: a prospective, observational study

    FavorávelEnsaio ClínicoAnsiedadeDepressãoDisfunção CognitivaAyahuasca+1
  227. 2019

    Age‐varying effects of cannabis use frequency and disorder on symptoms of psychosis, depression and anxiety in adolescents and adults

    DesfavorávelMetanáliseDependência — CannabisAnsiedadeDepressão
  228. 2019

    Association of CNR1 genotypes with changes in neurocognitive performance after eighteen-month treatment in patients with first-episode psychosis

    InconclusivoMetanáliseDisfunção CognitivaDoenças NeurodegenerativasEsquizofrenia
  229. 2019

    Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition

    DesfavorávelEnsaio Clínico Duplo-CegoDisfunção CognitivaTetraidrocanabinol (THC)
  230. 2019

    Cannabidiol (CBD) use in psychiatric disorders: A systematic review.

    InconclusivoMetanáliseAnsiedadeTEPT
  231. 2019

    Cannabidiol as a potential treatment for psychosis

    FavorávelMetanáliseEsquizofrenia
  232. 2019

    Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis

    FavorávelEnsaio Clínico Duplo-CegoEsquizofrenia
  233. 2019

    Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis

    InconclusivoMetanáliseAnsiedadeDepressãoTranstorno Bipolar+2
  234. 2019

    Cannabis acute use impacts symptoms and functionality in a cohort of antipsychotic naïve First Episode of Psychosis individuals

    DesfavorávelMetanáliseEsquizofrenia
  235. 2019

    Cannabis and Psychosis Through the Lens of DSM-5

    InconclusivoMetanáliseEfeitos Adversos da CannabisEsquizofrenia
  236. 2019

    Cannabis and Psychosis: Are We any Closer to Understanding the Relationship?

    InconclusivoMetanáliseEsquizofrenia
  237. 2019

    Cannabis and psychosis: revisiting a nineteenth century study of 'Indian Hemp and Insanity' in Colonial British India

    InconclusivoMetanáliseEsquizofrenia
  238. 2019

    Cannabis and psychosis: triangulating the evidence

    DesfavorávelMetanálise
  239. 2019

    Cannabis in the Treatment of Traumatic Brain Injury: A Primer for Clinicians

    FavorávelMetanáliseDepressãoTraumatismo Cranioencefálico
  240. 2019

    Cannabis use and psychosis: a review of reviews

    DesfavorávelMetanáliseEsquizofrenia
  241. 2019

    Cannabis Use and the Risk of Psychosis and Affective Disorders

    DesfavorávelMetanáliseEsquizofreniaTranstorno Bipolar
  242. 2019

    Cannabis use disorders and psychiatric comorbidities

    InconclusivoMetanáliseDependência — CannabisAnsiedade
  243. 2019

    Cannabis use disorders may protect against certain disorders of the digestive organs in people with schizophrenia but not in healthy controls

  244. 2019

    Cannabis use in subjects at ultra high risk for psychosis

    DesfavorávelMetanáliseEsquizofrenia
  245. 2019

    Cannabis-induced altered states of consciousness are associated with specific dynamic brain connectivity states

    InconclusivoEnsaio ClínicoDisfunção CognitivaTranstornos de Comportamento
  246. 2019

    Cannabis, a Significant Risk Factor for Violent Behavior in the Early Phase Psychosis. Two Patterns of Interaction of Factors Increase the Risk of Violent Behavior: Cannabis Use Disorder and Impulsivity; Cannabis Use Disorder, Lack of Insight and Treatment Adherence

    DesfavorávelMetanáliseEfeitos Adversos da CannabisDependência — Cannabis
  247. 2019

    Characterizing psychosis-relevant phenomena and cognitive function in a unique population with isolated, chronic and very heavy cannabis exposure

    DesfavorávelMetanáliseEsquizofrenia
  248. 2019

    Clinical and cost-effectiveness of contingency management for cannabis use in early psychosis: the CIRCLE randomised clinical trial

  249. 2019

    Clinical Challenges in Patients with First Episode Psychosis and Cannabis Use: Mini-Review and a Case Study

  250. 2019

    Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis

    DesfavorávelEnsaio Clínico Duplo-CegoEsquizofrenia
  251. 2019

    Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings

    FavorávelMetanáliseAnsiedadeEpilepsiaDependência — Álcool+3
  252. 2019

    Facilitators and Barriers to Participating in a Randomized Controlled Trial of a Psychological Therapy for Substance Use

    InconclusivoEnsaio ClínicoDependência QuímicaDependência — CannabisEsquizofrenia
  253. 2019

    Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis

    InconclusivoMetanáliseEsquizofrenia
  254. 2019

    Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders

    FavorávelMetanáliseAnsiedadeDepressãoEpilepsia+3
  255. 2019

    Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans

  256. 2019

    Hypothalamic-pituitary-adrenal axis function and exposure to stress factors and cannabis use in recent-onset psychosis

    InconclusivoMetanáliseEsquizofrenia
  257. 2019

    Increased BDNF-TrkB signaling in the nucleus accumbens plays a role in the risk for psychosis after cannabis exposure during adolescence

    InconclusivoEstudo em AnimaisEsquizofreniaCanabinoides Sintéticos WIN-x
  258. 2019

    Mapping the pathways between recreational cannabis use and mood disorders: A Behaviour Sequence Analysis approach

    InconclusivoMetanáliseAnsiedadeDepressão
  259. 2019

    Measuring Disturbance of the Endocannabinoid System in Psychosis A Systematic Review and Meta-analysis

    InconclusivoMetanáliseEsquizofreniaEndocanabinoide (não especificado)
  260. 2019

    Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use

    DesfavorávelMetanáliseEsquizofrenia
  261. 2019

    Priority Considerations for Medicinal Cannabis-Related Research

    FavorávelMetanáliseDorCâncerAnsiedade+16
  262. 2019

    Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis

  263. 2019

    Psychotic-like experiences and cannabis use in adolescents from the general population

    InconclusivoMetanáliseEsquizofrenia
  264. 2019

    Stopping cannabis use benefits outcome in psychosis: findings from 10-year follow-up study in the PAFIP-cohort

    DesfavorávelMetanáliseEsquizofrenia
  265. 2019

    Stress-induced cortical dopamine response is altered in subjects at clinical high risk for psychosis using cannabis

    InconclusivoMetanáliseEsquizofrenia
  266. 2019

    The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning

    DesfavorávelEnsaio Clínico Duplo-CegoEsquizofrenia
  267. 2019

    The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study

    DesfavorávelMetanáliseEsquizofrenia
  268. 2019

    The Effect of Age of Initiation of Cannabis Use on Psychosis, Depression, and Anxiety among Youth under 25 Years

    InconclusivoMetanáliseAnsiedadeDepressãoEsquizofrenia
  269. 2019

    The influence of substance use on the effectiveness of antipsychotic medication: a prospective, pragmatic study

  270. 2019

    The interaction between the ZNF804A gene and cannabis use on the risk of psychosis in a non-clinical sample.

    DesfavorávelMetanáliseEsquizofrenia
  271. 2019

    The neuropsychological profiles of young psychosis patients with and without current cannabis use

    InconclusivoMetanáliseEsquizofrenia
  272. 2019

    The neuropsychopharmacology of cannabis: A review of human imaging studies

    DesfavorávelMetanáliseDependência QuímicaDependência — CannabisEsquizofrenia
  273. 2019

    The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review

  274. 2019

    The Relevance of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population

  275. 2018

    A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders

  276. 2018

    Acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia

    FavorávelEnsaio Clínico Duplo-CegoEsquizofrenia
  277. 2018

    Age moderates the association between frequent cannabis use and negative schizotypy over time

    InconclusivoMetanáliseEsquizofrenia
  278. 2018

    Attachment and therapeutic alliance in psychological therapy for people with recent onset psychosis who use cannabis

  279. 2018

    Cannabis and psychosis: what do we know and what should we do?

    DesfavorávelMetanáliseCanabinoide Sintético (não especificado)
  280. 2018

    Cannabis consumption and psychosis or schizophrenia development

    DesfavorávelMetanáliseEsquizofrenia
  281. 2018

    Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study

    FavorávelEnsaio ClínicoDependência QuímicaDependência — CannabisEsquizofrenia
  282. 2018

    Differences in demographic and clinical characteristics between cannabis users and non-drug users: A retrospective study of patients at first hospitalization due to psychotic symptoms

    InconclusivoMetanáliseEsquizofrenia
  283. 2018

    Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer

  284. 2018

    Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial

  285. 2018

    Impact of comprehensive treatment for first episode psychosis on substance use outcomes: A randomized controlled trial

    InconclusivoMetanálise ClínicaDependência QuímicaDependência — CannabisDependência — Álcool+1
  286. 2018

    Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC

    FavorávelEnsaio Clínico Duplo-CegoEfeitos Adversos da Cannabis
  287. 2018

    Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function.

    DesfavorávelEnsaio Clínico Duplo-CegoDisfunção CognitivaTetraidrocanabinol (THC)
  288. 2018

    Longitudinal assessment of the effect of cannabis use on hospital readmission rates in early psychosis: A 6-year follow-up in an inpatient cohort

    DesfavorávelMetanáliseEsquizofrenia
  289. 2018

    Marijuana and Psychosis: Policy Implications for Treatment Providers

    DesfavorávelMetanáliseEsquizofrenia
  290. 2018

    Maternal and paternal cannabis use during pregnancy and risk of psychotic symptoms in the offspring.

    DesfavorávelMetanáliseEsquizofrenia
  291. 2018

    Maternal and paternal cannabis use during pregnancy and the risk of psychotic-like experiences in the offspring

    DesfavorávelMetanáliseGestação
  292. 2018

    Modulation of acute effects of delta-9-tetrahydrocannabinol on psychotomimetic effects, cognition and brain function by previous cannabis exposure

    InconclusivoEnsaio Clínico Duplo-CegoEfeitos Adversos da CannabisDisfunção CognitivaTetraidrocanabinol (THC)
  293. 2018

    Posttraumatic Stress Symptoms and Emerging Adult Sexual Minority Men: Implications for Assessment and Treatment of Childhood Sexual Abuse

    FavorávelMetanáliseDependência QuímicaDependência — CannabisAnsiedade+6
  294. 2018

    Probing the endocannabinoid system in healthy volunteers: Cannabidiol alters fronto-striatal resting-state connectivity

    FavorávelEnsaio Clínico Duplo-CegoAnsiedadeEsquizofreniaTetraidrocanabinol (THC)
  295. 2018

    Repeated Exposure to the “Spice” Cannabinoid JWH-018 Induces Tolerance and Enhances Responsiveness to 5-HT1A Receptor Stimulation in Male Rats

    DesfavorávelEstudo em AnimaisIntoxicação por Cannabis SintéticaCanabinoides Sintéticos JWH-x
  296. 2018

    The efficacy of a working memory training in substance use patients: A randomized double-blind placebo-controlled clinical trial

    InconclusivoEnsaio Clínico Duplo-CegoDependência QuímicaEfeitos Adversos da CannabisDependência — Cannabis+3
  297. 2018

    Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial

  298. 2017

    A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia

    FavorávelMetanáliseInflamaçãoDisfunção CognitivaDoenças Neurodegenerativas+5
  299. 2017

    Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model.

    FavorávelEstudo em AnimaisEsquizofrenia
  300. 2017

    Influence of childhood trauma on diagnosis and substance use in first-episode psychosis

    DesfavorávelMetanáliseDependência QuímicaDependência — CannabisAnsiedade+7
  301. 2017

    The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group

    DesfavorávelEnsaio ClínicoAnsiedade
  302. 2016

    Are deficits in cognition associated with psychotic-like experiences after cannabis?

    DesfavorávelMetanáliseEfeitos Adversos da CannabisDisfunção Cognitiva
  303. 2016

    Effect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence

    DesfavorávelMetanálise
  304. 2016

    Therapeutic alliance in psychological therapy for people with recent onset psychosis who use cannabis

  305. 2015

    Does cannabis affect dopaminergic signaling in the human brain? A systematic review of evidence to date

    InconclusivoMetanálise ClínicaTetraidrocanabinol (THC)
  306. 2015

    Genetic moderation of the effects of cannabis: catechol-O-methyltransferase (COMT) affects the impact of Δ9-tetrahydrocannabinol (THC) on working memory performance but not on the occurrence of psychotic experiences

    InconclusivoEnsaio Clínico Duplo-CegoDisfunção Cognitiva
  307. 2015

    The psychosis-like effects of Δ(9)-tetrahydrocannabinol are associated with increased cortical noise in healthy humans

    DesfavorávelEnsaio Clínico Duplo-CegoEfeitos Adversos da CannabisTetraidrocanabinol (THC)
  308. 2012

    Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers

    DesfavorávelEnsaio Clínico Duplo-CegoEfeitos Adversos da CannabisAnsiedade
  309. 2012

    Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment

    DesfavorávelEnsaio ClínicoDisfunção Cognitiva
  310. 2012

    Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers

    InconclusivoEnsaio Clínico Duplo-Cego
  311. 2012

    Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clinical trial

  312. 2012

    Does olanzapine inhibit the psychomimetic effects of Δ⁹-tetrahydrocannabinol?

    FavorávelEnsaio Clínico Duplo-CegoEfeitos Adversos da Cannabis
  313. 2012

    Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing

    InconclusivoEnsaio Clínico Duplo-Cego
  314. 2012

    Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders

    FavorávelMetanáliseAnsiedadeDepressão
  315. 2011

    Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study

    FavorávelEnsaio Clínico Duplo-CegoAnsiedadeDisfunção CognitivaTetraidrocanabinol (THC)
  316. 2011

    Substance use disorder among people with first-episode psychosis: a systematic review of course and treatment

    DesfavorávelMetanálise ClínicaDependência Química
  317. 2010

    Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review

    DesfavorávelMetanálise ClínicaDepressão
  318. 2009

    Cannabis and psychosis: search of a causal link through a critical and systematic review

    DesfavorávelMetanálise ClínicaTetraidrocanabinol (THC)
  319. 2008

    Effects of cannabis use on outcomes of psychotic disorders: systematic review

    DesfavorávelMetanálise Clínica
  320. 2007

    Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review

    DesfavorávelMetanálise Clínica
  321. 2006

    Comorbidity between substance use disorders and psychiatric conditions

    DesfavorávelMetanáliseDependência QuímicaAnsiedadeDepressão
  322. 2006

    Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis

    DesfavorávelEnsaio Clínico
  323. 2005

    Cannabis--psychosis pathway independent of other types of psychopathology

    DesfavorávelEnsaio ClínicoTetraidrocanabinol (THC)
  324. 2003

    Characteristics of subgroups of individuals with psychotic illness and a comorbid substance use disorder

    DesfavorávelEnsaio ClínicoDependência Química
  325. 2000

    Risperidone compared to haloperidol in cannabis-induced psychotic disorder: A double blind randomized controlled trial

    DesfavorávelEnsaio ClínicoEfeitos Adversos da Cannabis
  326. 1999

    A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial

    InconclusivoEnsaio Clínico
  327. 1894

    Report of the Indian Hemp Drugs Commission, 1893-1894 (Volume 2)

    DesfavorávelMetanálise

Continue por aqui

Perguntas frequentes

Quantos estudos sobre psicose estão indexados no acervo?
São 407 estudos, publicados entre 1871 e 2024. O acervo inteiro tem 7.640 registros.
Que tipos de estudo predominam?
Metanálise: 231 · Ensaio Clínico Duplo-Cego: 61 · Ensaio Clínico: 56 · Metanálise Clínica: 34 · Estudo em Animais: 20 · Estudo Laboratorial: 5. A classificação segue o desenho declarado na fonte.
O que significa a classificação de resultado?
É uma leitura automatizada da conclusão de cada estudo, em três direções — favorável, inconclusivo e desfavorável. Aqui são 145 favoráveis, 107 inconclusivos e 155 desfavoráveis. Serve para navegar o acervo, não para concluir nada clinicamente: a conclusão válida é a do artigo original.

Como citar esta página

ABNT

CANNABIS INDICA. Psicose — estudos científicos sobre cannabis. 2026. Disponível em: https://cannabisindica.com.br/condicao/psicose/. Acesso em: 13 set. 2026.

APA

Cannabis Indica. (2026). Psicose — estudos científicos sobre cannabis. https://cannabisindica.com.br/condicao/psicose/

Esta página é um índice de acesso. Ao usar um estudo como evidência, cite o artigo original — o link de cada registro leva à fonte.